Portrazza (Eli Lilly and Company)
Welcome to the PulseAid listing for the Portrazza drug offered from Eli Lilly and Company. This Epidermal Growth Factor Receptor Antagonist [EPC],HER1 Antagonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Eli Lilly and Company |
| NON-PROPRIETARY NAME: | necitumumab |
| SUBSTANCE NAME: | NECITUMUMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Epidermal Growth Factor Receptor Antagonist [EPC],HER1 Antagonists [MoA] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 2015-11-24 |
| END MARKETING DATE: | 0000-00-00 |
Portrazza HUMAN PRESCRIPTION DRUG Details:
| Item Description | Portrazza from Eli Lilly and Company |
| LABELER NAME: | Eli Lilly and Company |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 16(mg/mL) |
| START MARKETING DATE: | 2015-11-24 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0002-7716_62de9272-71de-4b81-8ccf-ad7806f02081 |
| PRODUCT NDC: | 0002-7716 |
| APPLICATION NUMBER: | BLA125547 |
Other NECITUMUMAB Pharmaceutical Manufacturers / Labelers:
